168 related articles for article (PubMed ID: 9612566)
21. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
24. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases.
Quesada AR; Barbacid MM; Mira E; Fernández-Resa P; Márquez G; Aracil M
Clin Exp Metastasis; 1997 Jan; 15(1):26-32. PubMed ID: 9009103
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
27. [Basic metalloproteinases of the connective tissue matrix].
Solov'eva NI
Bioorg Khim; 1994 Feb; 20(2):143-52. PubMed ID: 8155077
[TBL] [Abstract][Full Text] [Related]
28. Mechanical stretching of human saphenous vein grafts induces expression and activation of matrix-degrading enzymes associated with vascular tissue injury and repair.
Meng X; Mavromatis K; Galis ZS
Exp Mol Pathol; 1999 Aug; 66(3):227-37. PubMed ID: 10486241
[TBL] [Abstract][Full Text] [Related]
29. The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies.
Reynolds JJ; Meikle MC
J R Coll Surg Edinb; 1997 Jun; 42(3):154-60. PubMed ID: 9195805
[TBL] [Abstract][Full Text] [Related]
30. Gelatinases A and B.
Murphy G; Crabbe T
Methods Enzymol; 1995; 248():470-84. PubMed ID: 7674939
[No Abstract] [Full Text] [Related]
31. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis.
Sato H; Seiki M
J Biochem; 1996 Feb; 119(2):209-15. PubMed ID: 8882706
[TBL] [Abstract][Full Text] [Related]
32. The binding of gelatinases A and B to type I collagen yields both high and low affinity sites.
Allan JA; Docherty AJ; Murphy G
Ann N Y Acad Sci; 1994 Sep; 732():365-6. PubMed ID: 7978809
[No Abstract] [Full Text] [Related]
33. Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures.
Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL
Drug Des Discov; 1996 Apr; 13(3-4):3-14. PubMed ID: 8874040
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the interaction of TIMP-2 and MMPs: engineering the changes.
Hutton M; Butler GS; Wattam BA; Willenbrock F; Williamson RA; Murphy G
Ann N Y Acad Sci; 1999 Jun; 878():524-7. PubMed ID: 10415762
[No Abstract] [Full Text] [Related]
35. Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin.
Arbeláez LF; Bergmann U; Tuuttila A; Shanbhag VP; Stigbrand T
Arch Biochem Biophys; 1997 Nov; 347(1):62-8. PubMed ID: 9344465
[TBL] [Abstract][Full Text] [Related]
36. [Metalloproteinases in the extracellular matrix: structure and activity].
Cuvelier A; Kuntz C; Sesboüé R; Muir JF; Martin JP
Rev Mal Respir; 1997 Jan; 14(1):1-10. PubMed ID: 9082500
[TBL] [Abstract][Full Text] [Related]
37. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation.
Nagase H; Suzuki K; Itoh Y; Kan CC; Gehring MR; Huang W; Brew K
Adv Exp Med Biol; 1996; 389():23-31. PubMed ID: 8860990
[No Abstract] [Full Text] [Related]
38. Matrix metalloproteinases and their inhibitors in tumour growth and invasion.
Kähäri VM; Saarialho-Kere U
Ann Med; 1999 Feb; 31(1):34-45. PubMed ID: 10219712
[TBL] [Abstract][Full Text] [Related]
39. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth.
Fowlkes JL; Serra DM; Nagase H; Thrailkill KM
Ann N Y Acad Sci; 1999 Jun; 878():696-9. PubMed ID: 10415811
[No Abstract] [Full Text] [Related]
40. Matrix metalloproteinases.
Johnson LL; Dyer R; Hupe DJ
Curr Opin Chem Biol; 1998 Aug; 2(4):466-71. PubMed ID: 9736919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
